Antibodies specific to delta 1 chain of T cell receptor

Patent metadata

Field	Value
Publication number	US-12084500-B2
Application number	US-202017424474-A
Country	US
Kind code	B2
Filing date	Jan 23, 2020
Priority date	Jan 23, 2019
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

Disclosed herein are antibodies specific to a delta-1 chain of a γδ T cell receptor and methods of using such for modulating γδ T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with γδ T cell activation, such as solid tumors, or for detecting presence of γδ1 T cells.

First claim

What is claimed is:

1. An isolated antibody, which binds a delta-1 chain of a T cell receptor, wherein the antibody comprises a heavy chain complementarity determining region 1 (VH-CDR1) set forth as SEQ ID NO: 68, a heavy chain complementarity determining region 2 (VH-CDR2) set forth as SEQ ID NO: 53, and a heavy chain complementarity determining region 3 (VH-CDR3) set forth as SEQ ID NO: 54 and comprises a light chain complementarity determining region 1 (VL-CDR1) set forth as SEQ ID NO: 55, a light chain complementarity determining region 2 (VL-CDR2) set forth as SEQ ID NO: 56, and a light chain complementarity determining region 3 (VL-CDR3) set forth as SEQ ID NO: 57.

2. The isolated antibody of claim 1 , which is a full-length antibody or an antigen-binding fragment thereof.

3. The isolated antibody of claim 1 , which is a single chain antibody.

4. The isolated antibody of claim 1 , which is a human antibody or a humanized antibody.

5. The isolated antibody of claim 1 , which is an IgG molecule.

6. The isolated antibody of claim 5 , wherein the antibody is an IgG1 or IgG4 molecule.

7. The isolated antibody of claim 6 , wherein the antibody is an IgG1 molecule.

8. The isolated antibody of claim 7 , wherein the IgG1 has one or more mutations selected from (1) E333A mutation; (2) S239D/A330L/1332E mutation; (3) K326W/E333S mutations; (4) S239D/1332E/G236A mutation.

9. The isolated antibody of claim 7 , wherein the antibody comprises a heavy chain constant region set forth as SEQ ID NO: 31, and a light chain constant region set forth as SEQ ID NO: 73.

10. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain variable region (VH) set forth as SEQ ID NO: 24 and a light chain variable region (VL) set forth as SEQ ID NO: 9.

11. The isolated antibody of claim 10 , which is a full-length antibody or an antigen-binding fragment thereof.

12. The isolated antibody of claim 10 , which is a single chain antibody.

13. The isolated antibody of claim 10 , which is a human antibody or a humanized antibody.

14. The isolated antibody of claim 10 , which is an IgG molecule.

15. The isolated antibody of claim 14 , wherein the antibody is an IgG1 or IgG4 molecule.

16. The isolated antibody of claim 15 , wherein the antibody is an IgG1 molecule.

17. The isolated antibody of claim 16 , wherein the IgG1 has one or more mutations selected from (1) E333A mutation; (2) S239D/A330L/I332E mutation; (3) K326W/E333S mutations; (4) S239D/I332E/G236A mutation.

18. The isolated antibody of claim 16 , wherein the antibody comprises a heavy chain constant region set forth as SEQ ID NO: 31, and a light chain constant region set forth as SEQ ID NO: 73.

19. The isolated antibody of claim 10 , wherein the antibody comprises a VH set forth as SEQ ID NO: 24 and a VL set forth as SEQ ID NO: 9, and comprises a heavy chain constant region set forth as SEQ ID NO: 31 and a light chain constant region set forth as SEQ ID NO: 73.

20. The isolated antibody of claim 19 , wherein the antibody comprises a heavy chain set forth as SEQ ID NO: 79 and a light chain set forth as SEQ ID NO:78.

21. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising the antibody of claim 19 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition comprising the antibody of claim 20 and a pharmaceutically acceptable carrier.

26. A method of inhibiting γδ T cell activation in a subject, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of comprising the isolated antibody of claim 1 .

27. The method of claim 26 , wherein the subject in need thereof is a human patient having, suspected of having, or at risk for, a solid cancer.

28. The method of claim 27 , wherein the subject is a human patient having a solid tumor selected from the group consisting of pancreatic ductal adenocarcinoma (PDA), colorectal cancer (CRC), melanoma, breast cancer, lung cancer, upper and lower gastrointestinal malignancies, squamous cell head and neck cancer, genitourinary cancer, ovarian cancer, and sarcomas.

29. The method of claim 26 , further comprising administering to the subject an inhibitor of a checkpoint molecule, an activator of a co-stimulatory receptor, an inhibitor of an innate immune cell target, a chemotherapeutic agent, or an anti-hypertension agent.

30. The method of claim 29 , wherein the checkpoint molecule is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIM-3, A2aR, TIGIT and VISTA.

31. The method of claim 29 , wherein the co-stimulatory receptor is selected from the group consisting of OX40, GITR, CD137, CD40, CD27, and ICOS.

32. The method of claim 29 , wherein the innate immune cell target is selected from the group consisting of KIR, NKG2A, CD96, TLR, IDO, and galectin-9.

Assignees

• Univ New York
• Puretech Lyt Inc

Inventors

• Koide Shohei
• Miller George
• Koide Akiko
• Panchenko Tatyana
• Hattori Takamitsu
• Filipovic Aleksandra
• Elenko Eric
• Bolen Joseph

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title